In this issue ofArquivos de Neuropsiquiatria, Messias and colleagues report on a series of 41 patients with MOG antibody-associated disease (MOGAD) in a Brazilian tertiary center in São Paulo.1MOGAD presents a broad spectrum of clinical presentations and a detailed phenotype description is important to prevent misdiagnosis with other demyelinating diseases, such as multiple sclerosis or neuromyelitis optica spectrum disorder. Here, MOG is linked to neuromyelitis optica.